Sugi Predict

Sugi Predict / Compounds / SCHEMBL1709338

SCHEMBL1709338

SCHEMBL1709338

CCC(=O)NCc1ccc(F)cc1

nearest known ligand 0.70

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 3/20 0.70
▸ LMNA P02545 3/20 0.68
▸ KMT2A Q03164 1/20 0.65
▸ HTT P42858 1/20 0.64
▸ ALDH1A1 P00352 3/20 0.62
▸ RAB9A P51151 2/20 0.62
▸ TP53 P04637 2/20 0.60
▸ POLB P06746 2/20 0.56
▸ GAA P10253 1/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ PLA2G1B P04054 1/20 0.55
▸ ATG4B Q9Y4P1 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30259920 0.90 GAA (0.59) HPGDLMNAKMT2AHTTALDH1A1
SCHEMBL15672900 0.89 HPGD (0.57) HPGDLMNAKMT2AHTTALDH1A1
SCHEMBL23747789 0.87 ALDH1A1 (0.70) HPGDLMNAKMT2AALDH1A1RAB9A
SCHEMBL28313230 0.85 HPGD (0.81) HPGDLMNAKMT2AHTTALDH1A1
SCHEMBL826020 0.84 KMT2A (0.53) HPGDLMNAKMT2AHTTALDH1A1
SCHEMBL23933006 0.83 LMNA (0.66) HPGDLMNAKMT2AHTTALDH1A1
SCHEMBL13024401 0.82 TPSAB1 (0.50) HPGDLMNAALDH1A1
SCHEMBL13181415 0.82 KMT2A (0.61) HPGDKMT2AALDH1A1RAB9APOLB
SCHEMBL660986 0.82 KMT2A (0.62) HPGDLMNAKMT2AALDH1A1RAB9A
SCHEMBL21648724 0.82 EPHX2 (0.51) HPGDLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2945929-A1 ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-11-25 — — EP claimed
WO-2014111113-A1 ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-07-24 — — WO claimed
CN-118561801-A Benzo [ d ] [1,3] dioxoles compound, preparation method and application thereof 上海医药集团股份有限公司 2024-08-30 — — CN disclosed
US-11872236-B2 Pharmacological agents for treating ocular diseases CALASIA PHARMACEUTICALS, INC. (US) 2024-01-16 — — US disclosed
US-20230145782-A1 p53 MODULATORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-05-11 — — US disclosed
US-11072585-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. (US) 2021-07-27 — — US disclosed
US-20200115341-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2020-04-16 — — US disclosed
US-9884814-B2 Acylguanidines for treating osteoarthritis MERCK PATENT GMBH (DE) 2018-02-06 — — US disclosed
EP-2755985-B1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS IDENIX PHARMACEUTICALS LLC (US) 2017-11-01 — — EP disclosed
US-20150361037-A1 ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-12-17 — — US disclosed
EP-2945929-A1 ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-11-25 — — EP disclosed
WO-2014111113-A1 ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-07-24 — — WO disclosed
CN-103004006-B Additive for nonaqueous electrolyte, nonaqueous electrolyte, and electricity storage device SUMITOMO SEIKA CHEMICALS 2014-02-19 — — CN disclosed
CN-103004006-A Additive for nonaqueous electrolyte, nonaqueous electrolyte, and electricity storage device SUMITOMO SEIKA CHEMICALS 2013-03-27 — — CN disclosed
US-20130029967-A1 Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2013-01-31 — — US disclosed
US-20120088770-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PRISM BIOLAB CORPORATION (JP) 2012-04-12 — — US disclosed
US-5698552-A EXHIBIT PLATELET ACTIVATING FACTOR-ANTAGONISTIC ACTIVITY BOEHRINGER INGELHEIM KG (DE) 1997-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088770-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PLOD3, COL1A1, THPO HPGD 500/4885LMNA 255/4885KMT2A 3392/4885
US-20130029967-A1 Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors MTOR, PIK3CA, CDK2 HPGD 2492/4885LMNA 805/4885KMT2A 1289/4885
US-20200115341-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX HPGD 621/4885LMNA 175/4885KMT2A 963/4885
US-11072585-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof LOXL2, LOXL1, LOX HPGD 621/4885LMNA 175/4885KMT2A 963/4885
US-20230145782-A1 p53 MODULATORS AND USES THEREOF TP53, TP53BP1, MDM2 HPGD 604/4885LMNA 3115/4885KMT2A 3705/4885
US-11872236-B2 Pharmacological agents for treating ocular diseases CRYAA, CRYAB, TTR HPGD 1152/4885LMNA 480/4885KMT2A 4785/4885
US-20150361037-A1 ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS CTSG, CTSD, CTSB HPGD 137/4885LMNA 3320/4885KMT2A 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.